Related Experiment Video
Updated: Jan 3, 2026
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL
Xuan Zhang1, Dinesh Thummuri, Yonghan He
1Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1333 Center Drive, Gainesville, FL 32610, USA. zhengg@cop.ufl.edu.
Abstract:
BCL-XL, an anti-apoptotic BCL-2 family protein, plays a key role in cancer cell survival. However, the potential of BCL-XL as an anti-cancer target has been hampered by the on-target platelet toxicity because platelets depend on BCL-XL to maintain their viability. Here we report the development of a PROTAC BCL-XL degrader, XZ424, which has increased selectivity for BCL-XL-dependent MOLT-4 cells over human platelets compared with conventional BCL-XL inhibitors. This proof-of-concept study demonstrates the potential of utilizing a PROTAC approach to achieve tissue selectivity.
Insights
Researchers developed a novel PROTAC degrader, XZ424, targeting BCL-XL to reduce cancer cell survival. This approach offers improved selectivity, minimizing on-target platelet toxicity seen with traditional BCL-XL inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- BCL-XL is a crucial anti-apoptotic protein in the BCL-2 family, vital for cancer cell survival.
- Targeting BCL-XL presents a therapeutic challenge due to on-target platelet toxicity, as platelets rely on BCL-XL for viability.
Purpose of the Study:
- To develop a novel Proteolysis Targeting Chimera (PROTAC) BCL-XL degrader with enhanced selectivity.
- To evaluate the potential of PROTAC technology in achieving tissue-specific degradation of BCL-XL.
Main Methods:
- Development and characterization of XZ424, a PROTAC molecule designed to degrade BCL-XL.
- Comparative analysis of XZ424's efficacy and toxicity in BCL-XL-dependent cancer cells (MOLT-4) versus human platelets.
Main Results:
- XZ424 demonstrated increased selectivity for BCL-XL-dependent MOLT-4 cells compared to conventional BCL-XL inhibitors.
- The PROTAC approach showed reduced toxicity towards human platelets.
Conclusions:
- PROTAC technology offers a promising strategy for developing targeted cancer therapies with improved safety profiles.
- XZ424 represents a proof-of-concept for achieving tissue selectivity in BCL-XL targeted therapies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...